

5.60.051

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Central Nervous System Drugs	Original Policy Date:	May 14, 2021
Subject:	Apomorphine	Page:	1 of 4

Last Review Date: March 8, 2024

Apomorphine

Description

Apokyn (apomorphine) subcutaneous injection, Kynmobi (apomorphine) sublingual film

Background

Apomorphine is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D₄ receptor, and moderate affinity for the dopamine D₂, D₃, and D₅, and adrenergic α₁D, α₂B, α₂C receptors. The precise mechanism of action of apomorphine as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D₂-type receptors within the caudate-putamen in the brain (1-2).

Regulatory Status

FDA-approved indications:

- Apokyn is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease (1).
- Kynmobi is indicated for the acute, intermittent treatment of "off" episodes in patients with Parkinson's disease (2).

Apomorphine is contraindicated in patients using concomitant drugs of the 5HT₃ antagonist class including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron. There have been reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron (1-2).

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Central Nervous System Drugs	Original Policy Date:	May 14, 2021
Subject:	Apomorphine	Page:	2 of 4

Apomorphine may cause syncope, hypotension, or orthostatic hypotension. Patients taking concomitant antihypertensive medications or vasodilators should have blood pressure monitored (1-2).

There are reports of a dose related prolongation of QTc interval after apomorphine exposure. The risks and benefits of apomorphine treatment should be considered prior to initiating treatment with apomorphine in patients with risk factors for prolonged QTc (1-2).

The safety and effectiveness of apomorphine in pediatric patients less than 18 years of age have not been established (1-2).

Related policies

Inbrija, Nourianz, Nuplazid, Tasmar

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Apomorphine may be considered **medically necessary** if the conditions indicated below are met.

Apomorphine may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Parkinson's disease experiencing "off" episodes

AND ALL of the following:

1. Used in combination with carbidopa/levodopa
2. Inadequate control of Parkinson's off episodes on maximum tolerated doses of carbidopa/levodopa therapy

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Central Nervous System Drugs	Original Policy Date:	May 14, 2021
Subject:	Apomorphine	Page:	3 of 4

3. **NOT** used in combination with a 5HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron)
4. Prescriber agrees to monitor for QTc prolongation

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Parkinson's disease experiencing "off" episodes

AND ALL of the following:

1. Improvement in Parkinson's symptoms (e.g., reduction in daily off time, improvement in motor function post-administration)
2. Used in combination with carbidopa/levodopa
3. **NOT** used in combination with a 5HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron)
4. Prescriber agrees to monitor for QTc prolongation

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 6 months

Prior – Approval *Renewal* Limits

Duration 12 months

Rationale

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Central Nervous System Drugs	Original Policy Date:	May 14, 2021
Subject:	Apomorphine	Page:	4 of 4

Summary

Apomorphine is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D₄ receptor, and moderate affinity for the dopamine D₂, D₃, and D₅, and adrenergic α_1 D, α_2 B, α_2 C receptors. The precise mechanism of action of apomorphine as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D₂-type receptors within the caudate-putamen in the brain. The safety and effectiveness of apomorphine in pediatric patients less than 18 years of age have not been established (1-2).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of apomorphine while maintaining optimal therapeutic outcomes.

References

1. Apokyn [package insert]. Rockville, MD: MDD US Operations, LLC; June 2022.
2. Kynmobi [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; September 2022.

Policy History

Date	Action
May 2021	Addition to PA
September 2021	Annual review
March 2022	Annual review and reference update
March 2023	Annual review and reference update. Changed policy number to 5.60.051
December 2023	Annual review
March 2024	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 8, 2024 and is effective on April 1, 2024.